Criteria for inclusion included: (a) presence of anti‐AGO or FGFR3 antibodies, (b) coexistent autoimmune disorders (particularly Sjögren syndrome), or (c) clinical presentation indicative of an immune‐driven process. Here, FGFR3 is linked to Autoimmunity.